ArticleScientific reports2026
5-hydroxymethylcytosine signatures of tissue as potential predictive markers for platinum resistance in epithelial ovarian cancer patients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Platinum-based systemic therapy is the cornerstone of treatment for epithelial ovarian cancer (EOC). Although most patients initially respond to platinum-based therapy, they eventually develop drug resistance after multiple relapses. Currently, there is no effective method to predict platinum resistance in EOC patients. We collected EOC tissues from 50 patients, including 15 drug-resistant (DR) and 35 drug-sensitive (unDR) individuals. Genomic DNA (gDNA) was extracted from the cancer tissues for 5-hydroxymethylcytosine (5hmC) sequencing. Concurrently, we performed 5hmC-Seal on the cisplatin-sensitive ovarian carcinoma cell line A2780 and its isogenic cisplatin-resistant derivative, A2780-DDP. Differentially hydroxymethylated regions (DhMRs) were identified separately, and the intersection of these differentially modified genes was used to construct platinum resistance and prognosis prediction models via logistic regression. We identified 27 upregulated and 19 downregulated differentially expressed intersection genes, totaling 46 differentially hydroxymethylated insection genes. Each patient group was divided into training and validation cohorts for model development and validation. In this predictive model, we selected 12 5hmC markers to distinguish platinum resistance in EOC patients and 10 5hmC markers to differentiate between patients with short overall survival (OS ≤ 36 months, n = 16) and long OS (OS > 36 months, n = 34). The area under the curve (AUC) values were 0.937 (95% CI 0.733–1.000) and 0.971 (95% CI 0.785–1.000), respectively. We used 5hmC-Seal to detect differential changes associated with platinum resistance and sensitivity in EOC on the tissue and cell line levels. These 5hmC signatures represented promising preliminary predictive markers for platinum resistance and clinical outcomes in patients with EOC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.